Phathom Pharmaceuticals, Inc.
PHAT Nasdaq
SEC CIK 1783183
Follow Phathom Pharmaceuticals
Weekly email: filings, results, news
Revenue, last quarter
$74.3M
+88% vs same quarter last year
Net income
−$17.6M
+76.8% vs same quarter last year
EPS, diluted
−$0.21
+80% vs same quarter last year
Operating cash flow
−$1.9M
+96.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $175.1M | −$221.3K |
| FY24 | $55.3M | −$334.3K |
| FY23 | $682K | −$201.6K |
| FY22 | $0 | −$197.7M |
| FY21 | - | −$143.9M |
| FY20 | - | −$129.1M |
| FY19 | - | −$255.1M |
| FY18 | - | −$1.3M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.1% | −91.4% | −0.1% |
| FY24 | 85.6% | −502.2% | −0.6% |
| FY23 | 75.5% | −24532.6% | −29.6% |
| FY22 | - | - | - |
| FY21 | - | - | - |
| FY20 | - | - | - |
| FY19 | - | - | - |
| FY18 | - | - | - |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$167M |
| FY24 | −$266.9M |
| FY23 | −$139.2M |
| FY22 | −$147.6M |
| FY21 | −$148.8M |
| FY20 | −$70.7M |
| FY19 | −$36.6M |
| FY18 | - |
| FY17 | - |
- Phathom Pharmaceuticals
- Healthcare median
Show the numbers
| Year | Phathom Pharmaceuticals | Healthcare median |
|---|---|---|
| FY25 | −0.1% | −66.4% |
| FY24 | −0.6% | −87% |
| FY23 | −29.6% | −128.5% |
| FY22 | - | −143.6% |
| FY21 | - | −137.7% |
| FY20 | - | −134.3% |
| FY19 | - | −125.9% |
| FY18 | - | −172.7% |
| FY17 | - | −166.7% |
News
No stories filed under Phathom Pharmaceuticals yet - coverage appears here as the news feed clusters it.